FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, I	D.C. 20549
---------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol aTYR PHARMA INC [ LIFE ]									Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Shukla Sanjay					41					<u> </u>	L ]			X	Direc	tor		10% O	wner
(Last) (First) (Middle)						Date of Earliest Transaction (Month/Day/Year)							$\overline{}$	X	Office below	er (give title v)		Other (s	specify
3545 JOHN HOPKINS COURT, SUITE #250					11/21/2022								President and CEO						
(Street)					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
SAN DII	AN DIEGO CA 92121												X Form filed by One Reporting Person						
(City)	(St	ate) (Ž	Zip)	-											Form filed by More than One Reporting Person				orting
		Table	I - N	on-Deriva	tive S	Secur	rities	Ac	quire	d, Di	sposed of	f, or B	enefic	ially	Own	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye				/ear) i	Execution Date,		·	3. Transaction Code (Instr. 8) 4. Securities A Disposed Of (I					Beneficia		ties cially d Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)	Price	Transa		action(s) 3 and 4)			(111511.4)	
Common Stock 11/21/202					22				P		10,000	A	\$2.140	05 <sup>(1)</sup> 5		50,798		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)			7. Title Amou Secur Under Deriva Secur 3 and	nt of ities lying ative ity (Instr. 4)			9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Ownership	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exer	cisable	Expiration Date	Title	Amount or Number of Shares						

## **Explanation of Responses:**

## Remarks:

/s/ Nancy E. Denyes, 11/21/2022 Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>1.</sup> Represents weighted average price for the shares. The shares were purchased at prices ranging from \$2.13 to \$2.16 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price